Description

Pasireotide pamoate, also known as SOM230, is a synthetic long-acting somatostatin analogue that has been widely studied for its ability to bind multiple somatostatin receptor subtypes, including sst1, sst2, sst3, and sst5. Unlike traditional somatostatin analogues such as octreotide or lanreotide, Pasireotide demonstrates a broader receptor binding profile, with particularly high affinity for sst5. This expanded receptor affinity contributes to its unique pharmacological effects, making it a valuable compound in research investigating hormone hypersecretion, tumor cell proliferation, and apoptotic signaling pathways.

The pamoate salt form of Pasireotide provides enhanced stability and prolonged release characteristics compared to free peptide formulations. Its extended half-life makes it highly suitable for long-term experimental protocols, where sustained receptor modulation is required. Researchers have explored its applications in studies of Cushing’s disease, acromegaly, and neuroendocrine tumors, as well as in models of abnormal cell growth and endocrine dysregulation.

Manufactured under strict GMP standards, our Pasireotide pamoate is supplied at 99.47% purity, ensuring consistency and reproducibility in experimental outcomes. Available in both bulk wholesale and smaller laboratory quantities, it is an essential tool for institutions conducting cutting-edge research in endocrinology, oncology, and cellular signaling.

This compound is provided exclusively for laboratory research use and is not intended for human or veterinary administration.

Product Specifications

Mechanism of Action & Research Applications

Pasireotide pamoate acts as a potent agonist of somatostatin receptors, with binding affinity values (pKi) of 8.2 for sst1, 9.0 for sst2, 9.1 for sst3, and 9.9 for sst5, while exhibiting lower affinity for sst4. This receptor profile differentiates it from earlier somatostatin analogues, which predominantly target sst2. The broad receptor activity underlies its antisecretory, antiproliferative, and proapoptotic effects.

1. Endocrine Research:
   Pasireotide pamoate has been used in studies targeting hypercortisolism and growth hormone dysregulation. By binding to multiple receptor subtypes, it modulates hormone release from pituitary and peripheral endocrine tissues.

2. Oncology Research:
   The compound has been studied for its antiproliferative properties in neuroendocrine tumor models. Its ability to suppress growth factor signaling and induce apoptosis makes it a candidate for exploring tumor cell regulation.

3. Apoptotic Pathways:
   Experimental findings suggest Pasireotide enhances apoptotic signaling cascades in tumor and endocrine cells, leading to increased programmed cell death in hyperproliferative models.

4. Long-acting Research Tool:
   The pamoate formulation provides extended activity, supporting long-term studies that require continuous receptor engagement without frequent dosing.

Overall, Pasireotide pamoate represents a versatile research compound for investigating receptor pharmacology, endocrine disorders, and oncological pathways.

Side Effects (For Reference in Models)

In laboratory and preclinical research settings, Pasireotide pamoate has been associated with certain modeled side effects, including:

• Alterations in glucose metabolism and insulin signaling

• Gastrointestinal disturbances such as nausea or diarrhea (in model organisms)

• Potential bradycardia and cardiovascular effects in animal studies

• Modulation of liver enzyme levels and hepatic function markers

These effects are important considerations in experimental designs, particularly when investigating endocrine or metabolic pathways. All references to side effects are based on model studies and are for informational purposes only.

Disclaimer

Pasireotide pamoate provided by our GMP-certified facility is intended strictly for laboratory research use only. It is not approved for human consumption, medical treatment, or diagnostic applications. Wholesale and retail supply is available to academic institutions, laboratories, and research organizations.

Keywords

Pasireotide pamoate, SOM230, Pasireotide embonate, somatostatin analogue, GMP-grade Pasireotide, Pasireotide CAS 396091-79-5, endocrine research peptides, Pasireotide for oncology research, Pasireotide antiproliferative activity, Pasireotide apoptosis studies